A phase 2 clinical trial (NCT02395627) [10] evaluated patients with ER+ breast cancer upon treatment with histone deacetylase (HDAC) inhibitor (vorinostat), ER antagonist (tamoxifen) and PD1-blocking Ab (pembrolizumab). The gene discussed is ESR1; the disease is breast carcinoma.